TRCT
SXTP icon

Tower Research Capital (TRC)’s 60 Degrees Pharmaceuticals SXTP Stock Holding History

Tower Research Capital (TRC)’s Portfolio SXTP Stock Details SXTP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,685
Closed -$3.42K – 5549
2025
Q4 		$3.42K Buy
1,685
+900
+115% +$4.17K ﹤0.01% 4371
2025
Q3 		$4.65K Buy
785
+135
+21% +$823 ﹤0.01% 4310
2025
Q2 		$6.16K Buy
650
+262
+68% +$2.63K ﹤0.01% 4126
2025
Q1 		$2.85K Buy
388
+201
+107% +$2.47K ﹤0.01% 4494
2024
Q4 		$4.81K Buy
187
+113
+153% +$2.49K ﹤0.01% 4395
2024
Q3 		$1.84K Buy
74
+44
+147% +$1.63K ﹤0.01% 5096
2024
Q2 		$1.79K Buy
30
+1
+3% +$63 ﹤0.01% 5090
2024
Q1 		$1.81K Buy
29
+16
+123% +$1.78K ﹤0.01% 5180
2023
Q4 		$3.14K Buy
13
+1
+8% +$174 ﹤0.01% 5122
2023
Q3 		$2.22K Buy
+12
New +$4.98K ﹤0.01% 5195

Other funds holding SXTP

KCM
Kathmere Capital Management Wayne, Pennsylvania $1.89B AUM 26.04% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
TPWA
Twin Peaks Wealth Advisors Burlingame, California $442M AUM 29.95% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Tower Research Capital (TRC)'s SXTP Position: Q1 2026 in Review

Tower Research Capital (TRC) sold out of 60 Degrees Pharmaceuticals (SXTP) in Q1 2026, closing a stake of 1,685 shares — an estimated $3.42K sold.

Tower Research Capital (TRC) first reported a position in SXTP in Q3 2023 and held it in 10 quarters. The position peaked at $6.16K in Q2 2025. 8 funds tracked by Wall St. Rank hold SXTP as of Q1 2026.

  • Tower Research Capital (TRC) reported no remaining 60 Degrees Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 1,685 60 Degrees Pharmaceuticals shares in Q1 2026, an estimated $3.42K.
  • Tower Research Capital (TRC) first reported a position in 60 Degrees Pharmaceuticals in Q3 2023 and held it in 10 quarters.
  • Tower Research Capital (TRC)'s 60 Degrees Pharmaceuticals position peaked at $6.16K in Q2 2025.
  • 8 funds tracked by Wall St. Rank held 60 Degrees Pharmaceuticals as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.